anti-CD38 CAR T cells

Anti-CD38 CAR T cells are genetically engineered T lymphocytes expressing a chimeric antigen receptor (CAR) specific for CD38, a transmembrane glycoprotein highly expressed on multiple hematologic malignancies, including multiple myeloma (MM), acute myeloid leukemia (AML), and T-cell acute lymphoblastic leukemia (T-ALL)[1][5][9]. The CAR typically incorporates an extracellular single-chain variable fragment targeting CD38, coupled with intracellular signaling domains such as CD3ζ and 4-1BB for T cell activation and persistence[1]. These cells recognize and eliminate CD38-expressing tumor cells via cytolytic activity and cytokine production. Preclinical data demonstrate potent antitumor activity against various MM, AML, and T-ALL models[1][5][9]. Toxicity is a concern due to CD38 expression on some normal hematopoietic and non-hematopoietic tissues[5]. Several anti-CD38 CAR T constructs are in clinical trials for relapsed/refractory multiple myeloma, and potentially other CD38-positive malignancies[1][5][9]. This therapy is investigational and not yet FDA approved, but remains an area of active clinical development.

Other names

anti-CD38 CAR T lymphocytesanti-CD-38 CAR T lymphocytesanti-CD 38 CAR T lymphocytesCD38-redirected CAR T cellsCD-38-redirected CAR T cellsCD 38-redirected CAR T cellsanti-CD38 CAR-γδ T cells